P1.056. FLOT vs CROSS Neoadjuvant Regimens in Esophageal and Esophagogastric Junction Adenocarcinomas: Meta-Analysis of Matched Patient Populations

Clicks: 18
ID: 326119
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #310 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant treatment followed by surgical resection is standard of care for locally advanced oesophageal adenocarcinoma. Recent evidence has indicated that FLOT chemotherapy offers superior survival to CROSS chemoradiotherapy in this cohort. This study aims to meta-analyse all matched patient data comparing these two treatment regimens. Methods A systematic review of PubMed, Scopus and EMBASE was performed from January 2010 to December 2025. Randomized controlled trials (RCT) and propensity score matched studies (PSM) directly comparing FLOT and CROSS were included for analysis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool for RCTs and the ROBINS-I tool for non-randomised studies. A meta-analysis using random effects model was performed examining overall survival, three-year survival, R0 resection, pathological complete response rate (pCR) and peri-operative morbidity. Results 4 studies (One RCT, 3 PSM studies) comprising 824 patients were eligible for analysis. The pooled hazard ratio for overall survival significantly favoured FLOT (HR 0.79, CI 0.68 – 0.93). However, survival at three years was similar between the two regimens (OR 1.19, CI 0.89 – 1.60). There was no significant difference observed in achieving R0 resections (OR 0.77, CI 0.33 – 1.77) or pCR (OR 0.87, CI 0.45 – 1.70). With regards to perioperative outcomes, there were no differences observed in mortality (OR 0.54, CI 0.21 – 1.40), anastomotic dehiscence (OR 0.8, CI 0.48 – 1.34) or other major complications (OR 1.04, CI 0.71 – 1.5). Conclusion The result of this meta-analysis provides further evidence that perioperative FLOT chemotherapy confers a survival advantage over CROSS chemoradiotherapy in oesophageal adenocarcinoma. Additionally, CROSS chemoradiation did not appear to provide benefit in complete response rate or in achieving negative surgical margins when compared to chemotherapy alone.
Reference Key
openalex_W7203981567 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Colm Neary, Yasir Alshareefy, Mayilone Arumugasamy, Jarlath Bolger
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.204
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.204/70760194/doag077.204.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.